Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Ralliant Corp director Brian Worrell bought 2,500 shares of common stock on February 6, 2026, for $99,825 at a weighted average price of $39.93. The purchase occurred as the stock traded near its 52-week low and after a recent $1.44 billion non-cash goodwill impairment tied to EA Elektro-Automatik. Analysts' price targets and ratings on Ralliant va…
Ralliant Corp director Moorthy Ganesh acquired 2,000 shares on February 6, 2026, investing $79,480. The transaction comes amid a $1.44 billion goodwill impairment tied to EA Elektro-Automatik and varied analyst adjustments to price targets following a guidance miss and recent corporate results. The board also approved a small quarterly dividend pay…
Ceribell President and CEO Chao Xingjuan sold 38,994 shares of common stock on February 4, 2026, for $786,240 and exercised options to acquire 25,000 shares at $4.70. The company, valued at about $747 million, holds more cash than debt and has received FDA Breakthrough Device designation for its LVO stroke detection monitor. Ceribell is not profita…
Colgate-Palmolive CEO Noel R. Wallace disposed of 45,568 shares on February 4, 2026, generating $4,279,495 at a weighted average price of $93.9145. The company posted fourth-quarter EPS of $0.95, beating a $0.91 estimate, and a swath of analysts left or raised ratings and price targets on the stock.
PulteGroup director Thomas J. Folliard disposed of 37,000 shares on February 5, 2026, generating roughly $4.9 million in proceeds. The company also announced a quarterly cash dividend and attracted new analyst coverage as federal officials and industry leaders discussed incentives aimed at boosting housing affordability.
Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 37,685 shares of Merck & Co. Inc. (MRK) common stock on February 6, 2026, at a weighted average price of $120.9241 per share, generating proceeds of $4,557,024. The sale left DeLuca with 160,173.834 shares directly owned. In the same period, several analyst firms…
NAPCO Security Technologies CEO Richard Soloway sold 150,000 shares on February 5, 2026, for roughly $6.4 million. The move comes after a strong share-price run and follows a fiscal second-quarter beat that prompted analysts to raise price targets and reaffirm ratings. Despite healthy financials, one valuation model flags the stock as overvalued re…
Merck & Co.'s Executive Vice President and CFO, Caroline Litchfield, sold 41,997 shares on February 4, 2026, raising roughly $5.02 million after exercising options. The move comes alongside Merck's first 2026 revenue guidance and a wave of analyst target adjustments reflecting differing views on the company's near-term headwinds and longer-term opp…
Viavi Solutions President and CEO Oleg Khaykin sold 70,566 shares on February 6, 2026, at prices between $26.25 and $26.30 for proceeds totaling $1.85 million. The divestiture occurred while Viavi shares traded near a 52-week peak and after the company posted second-quarter fiscal 2026 results that modestly beat expectations.
Murphy USA Inc. (MUSA) said President and CEO West Malynda K sold 3,967 shares of common stock at $450.00 on February 4, 2026, for roughly $1.78 million. The transaction was conducted under a Rule 10b5-1 plan adopted in August 2025. The company reported fourth-quarter 2025 results with an EPS of $7.53, beating the $6.45 estimate, while revenue of $…
William Rand Cook, a director at Primis Financial Corp (NASDAQ:FRST), purchased 1,410 shares on February 5, 2026, for $20,113 as the regional bank's stock trades close to its 52-week high. The company reported fourth-quarter 2025 earnings and revenue that substantially exceeded analyst projections, while valuation metrics show a low price-to-earnin…
Samir Mehta, president of Space & Missions Systems at L3Harris Technologies, sold 4,840 company shares on February 5, 2026, for $338.85 per share, netting $1.64 million. The transaction, reported on a Form 4 filing with the SEC, leaves Mehta with 5,916.07 directly held shares. Separately, L3Harris posted fourth-quarter 2025 results that beat EPS ex…
Richard A. Hayne, CEO and chairman of Urban Outfitters Inc (URBN), disposed of $2,901,811 of company stock across a series of prearranged transactions on February 4 and 5, 2026. The trades included shares held directly by Hayne and shares held indirectly by his spouse as trustee. Urban Outfitters continues to show revenue growth and strong Investin…
Knowles Corp President and CEO Jeffrey Niew sold 75,000 shares of company stock on February 6, 2026, in three transactions totaling $1,987,500. The disposition occurred while the shares traded near a 52-week high and follows strong fourth-quarter results and an Outperform reiteration from Baird. The sales were executed under a Rule 10b5-1 plan adop…
William D. Waddill, a director at Protagonist Therapeutics (PTGX), sold 20,000 shares on February 6, 2026, for about $1.67 million and concurrently exercised options to acquire an additional 20,000 shares at $8.31 each. The transactions leave him with 7,825 directly held shares. The moves coincide with a flurry of analyst updates after Protagonist …
Evercore Inc. General Counsel Jason Klurfeld completed a sale of Class A shares worth $1.8 million and surrendered additional shares to cover taxes tied to vesting restricted stock units. The transactions leave him with just under 50,000 shares. The moves come as Evercore reported stronger-than-expected Q4 2025 results and saw a slight upward revis…
Director Curtis W. Stoelting sold 9,000 shares of Regal Rexnord (RRX) stock on February 4 and 5, 2026, under a pre-established Rule 10b5-1 trading arrangement, realizing $1.71 million. The company recently reported fourth-quarter 2025 results that beat revenue and adjusted earnings expectations, and KeyBanc raised its price target to $200 while kee…
Albert Brad Delco, Executive Vice President and Chief Financial Officer of J.B. Hunt Transport Services Inc. (NASDAQ: JBHT), sold 1,000 shares on February 6, 2026 for $227.25 per share, totaling $227,250. The company also reported fourth-quarter earnings that beat consensus, prompted analyst target adjustments, raised its quarterly dividend by 2.3%…
Snap-on Senior Vice President Timothy L. Chambers sold 7,999 shares of company stock on February 4, 2026, realizing $3,081,009 in proceeds, and on the same day exercised options to acquire 8,000 shares for $1,104,240. The trades were disclosed in a Form 4 filing. The company recently reported mixed fourth-quarter 2025 results, with an EPS beat but …
James S. Johnson, a director at Bridgewater Bancshares Inc (NASDAQ: BWB), sold 4,712 shares on February 5, 2026, for a total of $92,893, according to a Form 4 filing with the SEC. Following the sale, Johnson retains direct and indirect holdings across trusts and an IRA. Separately, Bridgewater reported fourth-quarter 2025 results that topped analys…
FirstCash Holdings Executive Vice President and CFO R. Douglas Orr sold 7,500 shares of company stock on February 5, 2026, generating $1,313,940 in proceeds across three transactions executed under a pre-established 10b5-1 plan. The trades leave Orr and related trusts and partnerships with substantial holdings, while Canaccord Genuity reaffirmed a …
Jessie Hanrahan, Chief Regulatory Officer at Solid Biosciences Inc (SLDB), sold 12,348 shares on February 4, 2026, receiving $79,544. The sale, executed to cover withholding taxes tied to the vesting of restricted stock units, follows a year in which SLDB shares rose roughly 126%. The company also reported clinical and regulatory milestones includi…
Solid Biosciences Chief Technology Officer Paul Herzich sold 10,905 shares on February 4, 2026, to cover withholding taxes tied to vested restricted stock units. The transaction, executed at a weighted average price of $6.4419, leaves Herzich with 69,067 directly held shares. Solid Biosciences has reported clinical milestones across Duchenne and Fr…
Gabriel Brooks, Chief Medical Officer of Solid Biosciences Inc. (NASDAQ: SLDB), sold 12,616 shares on February 4, 2026, in a non-discretionary sell-to-cover transaction to satisfy withholding tax obligations after restricted stock units vested. The sale, executed under a pre-existing instruction, generated $81,271 at an average price of $6.4419 per…
Timothy J. Jahnke, a director at Zurn Elkay Water Solutions Corp, sold 17,900 shares on February 4, 2026 under a Rule 10b5-1 plan for $50.44 per share, totaling $902,876. The trade occurred as the stock traded close to its 52-week high and after the company reported revenue and adjusted EBITDA that exceeded analyst expectations. Analysts from Stife…
